Prevention Of Systemic Embolism Caused By A Clot In A Blood Vessel — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for prevention of systemic embolism caused by a clot in a blood vessel. 6 active patents protecting 1 drugs from 1+ originators. First major cliff: 2034. Daily refresh.

1
Approved drugs
6
Active US patents
62/100
Avg vulnerability
—
Annual revenue covered

Originators in Prevention Of Systemic Embolism Caused By A Clot In A Blood Vessel

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Johnson & Johnson 6 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating prevention of systemic embolism caused by a clot in a blood vessel. Each bar = one year. Y-axis scaled to peak year (6 patents).

6
34

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Xarelto
rivaroxaban
 Johnson & Johnson 6 62 — 2034-02-17

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9539218 Xarelto method of use 62 2034-02-17
9539218 Xarelto method of use 62 2034-02-17
9539218 Xarelto method of use 62 2034-02-17
9539218 Xarelto other 62 2034-08-17
9539218 Xarelto other 62 2034-08-17
9539218 Xarelto other 62 2034-08-17

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9539218 Xarelto other 62 2034-08-17
9539218 Xarelto other 62 2034-08-17
9539218 Xarelto other 62 2034-08-17
9539218 Xarelto method of use 62 2034-02-17
9539218 Xarelto method of use 62 2034-02-17
9539218 Xarelto method of use 62 2034-02-17

Related